Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Name Change For Takeda's Dexilant Shows Challenge Of Pre-Market Screening

Executive Summary

Sometime after Takeda released its heartburn treatment dexlansoprazole onto the U.S. market in January 2009, it noticed something strange in its post-marketing surveillance: the number of medication errors reported for the drug was not going down

You may also be interested in...



Dangerous Clutter: FDA Takes On Errors Caused By Drug Labels, Packaging

Reducing the amount of unnecessary information on drug labels is one of several key ways to stop dangerous medication errors, a panel that is helping FDA develop guidance on the subject agreed

Dangerous Clutter: FDA Takes On Errors Caused By Drug Labels, Packaging

Reducing the amount of unnecessary information on drug labels is one of several key ways to stop dangerous medication errors, a panel that is helping FDA develop guidance on the subject agreed

Regulatory News In Brief

Takeda heartburn drug gets name change: Takeda's proton pump inhibitor Kapidex (dexlansoprazole) will be marketed under a new brand name, Dexilant, starting in late April, in order to prevent confusion with two very dissimilar drugs with potentially similar names, the company and FDA announced March 4. FDA said it approved the name change to avoid confusion with AstraZeneca's prostate cancer treatment Casodex (bicalutamide) and Actavis' Kadian (morphine sulfate), an opiate pain reliever. Kapidex was approved in January 2009, and FDA said there have been reports of dispensing errors with the other two drugs since then, although neither the agency nor the company gave any details. The agency highlighted the change as a success for its Safe Use Initiative, which it began in November 2009 (1"The Pink Sheet" DAILY, Nov. 4, 2009). In a similar incident involving an OTC drug, FDA has asked Novartis to rebrand a Maalox line extension, Maalox Total Relief, a stomachache/diarrhea remedy. The agency said it received "five reports of serious medication errors involving consumers" that accidentally used Total Relief in place of the regular Maalox antacid products (2"The Tan Sheet," Feb. 22, 2010)

Related Content

Topics

UsernamePublicRestriction

Register

PS052283

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel